Stephen Yelity – President & CEO
Stephen created BusStim out of the need for an entrepreneurial implementation to leverage this veteran big pharma expertise and rich academia technology ecosystem here in NY, NJ and PA. He is a long-term entrepreneur with over 30 years of experience. At a young age, he left a successful career at Johnson & Johnson as Cost Accounting Manager to start ACCURATE Information Systems Inc. a cutting edge Information Technology Consulting firm. He built a management team around a group of PhD level, highly qualified software engineers, electrical engineers and computer experts from Bell Labs and academia. ACCURATE unleashed their skills and knowledge to work on some highly innovative and high profile projects. Steve and his team built ACCURATE to an $18 Million – 110 employee’s organization. For over 10 years, he teamed with other entrepreneurs to design/refine business models and structure alliances to start or expand their businesses. A few years ago, he observed the state of the industry in Big Pharma country and decided to pull together an organization to stimulate the situation with the creation of BusStim. As a result of his many years of experience in several successful ventures and startups, Stephen has the passion, energy level, consulting industry experience and creativity to build a vision for a team to follow.
K. “Ajay” Kumar, Ph.D. MBA – Vice President of Drug Development & Strategy
Dr. Kumar originally worked after his PhD on Paclitaxel “TAXOL” a blockbuster BMS oncology agent. Later, he moved to Taxolog where he was leading a large drug discovery group involved in the discovery of novel drugs in the Oncology and RA (autoimmune) arena. He was later leading the drug development effort having transitioned to managing the pre-clinical and early clinical programs. He was involved during this phase in some major licensing deals for drugs that came out of this pipeline. He was also managing alliances with development partners during this period. In 2009 Dr. Kumar was part of the founding members of Symbiotic Research LLC, a CRO in the Life Sciences area. He functioned as Chief Scientific Officer and one of the managing members of Symbiotic with overall general management responsibility and was able to in-license an oncology drug and takes it through Phase I clinical trial. The drug is on track for Phase II trial in 3 indications. He is well versed in the application of financial and operational tools in business including design and implementing of strategy. With his financial background he has invaluable experience in firm level valuations and can evaluate merger and acquisition scenarios, including valuations of difficult to evaluate young companies, IP rich companies and companies with negative growth and or hidden liabilities. He has a PhD in Life Sciences and a MBA in finance from Rutgers and he has been elected to the BGS-business honor society. Dr. Kumar also has over 36 patents and publications.
Thomas Argentieri, Ph.D. Vice President of Business Development & Alliance Management
Dr. Thomas Argentieri is a Pharma and Biotech Executive with over 30 years of experience in academic, Pharma and Biotech R&D. Dr. Argentieri received his Ph.D. in pharmacology from the New Jersey Medical School (Rutgers University) focusing on ion channel biophysics, and received post-doctoral training at the University of Pennsylvania. He spent several years as a research assistant professor at the University of Pennsylvania's department of medicine studying mechanisms of cardiac arrhythmias. From there Dr. Argentieri was Section Head at Berlex Pharmaceuticals, helping to build and lead their antiarrhythmic and antihypertensive drug discovery efforts putting 2 drugs into the clinic. Seven years later he was recruited by Wyeth Pharmaceuticals to direct their Urologic Disorders division where he oversaw the development of novel ion channel modulators and beta-3 adrenergic receptor agonists for the treatment of over active bladder. During this time period he authored over 70 peer reviewed manuscripts, review articles and book chapters, and was awarded 10 patents. After over 20 years in R&D, he transitioned into business development performing in-licensing and out-licensing activities for the pharmaceutical and Biotech industries and conducted numerous deals on both the buy and sell side. Dr. Argentieri is the owner and founder of BioSense Solutions, a company that provides scientific evaluation, market research, licensing and business development expertise to the pharmaceutical and biotech industries. He currently serves on the editorial boards of the Journal of Pharmacology and Experimental Therapeutics (JPET) and the Open Pharmacology Journal.
Douglas Greene, MD, Chief Medical Officer & Clinical Advisor
Dr. Greene is Founder and Lead Consultant of Dagphamed. He was the Executive Vice President, Chief Scientific Officer at IKARIA from May 2014 to October 2015, before which he served as our Executive Vice President, Research and Development. Prior to joining us, from April 2009 to April 2010, Dr Greene served as Senior Vice President and Senior Scientific Advisor at Sanofi-aventis, a global pharmaceutical company. From August 2006 to March 2009, Dr Greene served as Senior Vice President and Chief Medical Officer of the US business at Sanofi-aventis. From June 2003 to July 2006, Dr Greene served as Vice President and Head of Corporate Regulatory Development at Sanofi-aventis. Dr Greene was Executive Vice President of Clinical Sciences and Product Development at Merck Research Laboratories and Corporate Officer of Merck, Inc., a global pharmaceutical company, from May 2000 to January 2003. Dr Greene also was a member of the US Food and Drug Administration’s Endocrinologic and Metabolic Drug Advisory Committee from 1988 to 1994, and acted as Chairman of the Advisory Committee from 1990 to 1994. From 1986 to 2000, Dr. Greene was Professor of Internal Medicine, Director of the Michigan Diabetes Research and Training Center, and Chief, Division of Endocrinology & Metabolism at the University of Michigan School of Medicine. Dr Greene holds an MD from the Johns Hopkins School of Medicine and an AB from Princeton University.
Paul Jeffrey – Senior Business Development Advisor
Paul is an experienced business leader and advisor with over 30 years of pharmaceutical product development and marketing experience. He is presently owner of PJ BioPharma Solutions LLC, a business advisory company. He serves on Advisory Boards for several small and start-up biopharma companies. Prior to consulting, Paul was Vice President of Early Commercial Development at Pfizer for all Rx products in Primary Care.
Paul’s diverse background includes basic research as a chemist, new product development and commercialization, and US and global marketing. He has also served in various roles in biopharma business development including deal design, negotiation and implementation. He led joint marketing and co-development teams with partner companies from small biotechs such as XOMA to large pharma companies such as BMS. He has a proven track record of developing talent and leading multidisciplinary teams of professionals to successfully develop new pharmaceuticals.
As a consultant, Paul is using his talent and broad knowledge of pharmaceutical development and deal making to help small biotech companies maximize their product or company value to potential partners.
He is on advisory boards for Quantex Labs, BusStim, Versi Group, and High Throughput Biology. He recently aided in positioning Excaliard Pharmaceuticals for acquisition by Pfizer and in completing asset/technology evaluation for Oligomerix’ products for Alzheimer’s. He earned a MBA from New York
University, MS in Organic Chemistry from MIT and BS in Chemistry from Carnegie-Mellon University.
Business Stimulant Consultants, LLC
3240 Henry Hudson Parkway
Riverdale, NY 10463